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The ketogenic diet (KD) is a high-fat, low carbohydrate nutritional treatment adopted in
several countries for refractory epilepsy. However, the use of KD is limited by adverse
events including growth retardation. In a previous investigation, we demonstrated that
ghrelin is reduced in children maintained on KD for 3 months. As ghrelin regulates growth
hormone (GH) secretion, it can be hypothesized that growth retardation depends on the
reduced ghrelin availability. To assess this hypothesis, in this study we evaluate ghrelin
and growth during 1 year of KD. We examined a small cohort of 6 children (2 males
and 4 females, age range 3–10.4 years) affected by refractory epilepsy, who received the
KD as add-on treatment. All patients were on drug polytherapy. Endpoints of the study
were: (i) ghrelin plasma levels at 0, 15, 30, 90, and 365 days from KD onset, (ii) growth,
and (iii) seizure control by ketogenesis. Ghrelin levels were −53 and −47% of basal
levels, respectively, at 90 and 365 days (P < 0.05 for both). Mean height index z scores
were reduced, but not significantly, by comparing basal values with those at the end of
observation. Instead, body mass index z scores slightly increased. Ketosis induced by
the KD was within 2–5 mmol/L and satisfactorily reduced the seizure frequency (>50%)
in all patients. We show that ghrelin plasma levels are consistently reduced in children
with refractory epilepsy and maintained on the KD. This change was associated with low
growth indexes in the majority of patients.
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INTRODUCTION
A high-fat, low-carbohydrate and normal protein diet has been developed, and named “ketogenic
diet (KD),” to control antiseizure drug (ASD)-refractory epilepsy. This diet was designed to induce
ketone body production, so to reproduce the physiological changes associated with prolonged
fasting (1). In children with refractory seizures, the KD may be effective in up to 87% of cases
(2). In spite of its demonstrated usefulness (3), various adverse events among which the most
consistent is growth retardation (4–9) may limit the diffusion of KD as a medical nutritional
treatment. Growth impairment in patients on the KD has been related to dysfunctional production
of insulin-like growth factor-1 (IGF-1) (8), probably resulting from the alteration of mechanisms
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regulating growth hormone (GH) production. To this regard, the
growth hormone secretagogue (GHS) ghrelin, which is a major
regulator of food intake, metabolism, and GH secretion (10),
could be responsible for the growth impairment and maybe for
the reduction of IGF-1 observed in children on the KD.
Ghrelin is a peptide hormone prevalently released by gastric
P/D1 cells and has also been involved in memory (11), anxiety
(12), epilepsy (13), and neuroprotection (14). Interestingly,
ghrelin is markedly dysregulated in pediatric patients with
epilepsy and treated with ASDs (15). In addition, ghrelin has
been associated with body weight gain in children with epilepsy
and receiving valproate, thus suggesting an association between
ghrelin and dysregulation of metabolism in epilepsy (16). In
view of this evidence, we recently observed a time-dependent
reduction in ghrelin plasma levels in children with refractory
epilepsy and maintained on the KD (2). However, in these
children we noticed a stable growth during the short 90 days’
period of observation. For this reason, we decided to extend
our previous study to establish if ghrelin levels could be stably
reduced after 1 year of KD in children with refractory epilepsy,
and the possible impact of the hypothesized ghrelin reduction on




We considered a small cohort of 6 subjects composed by
2 males and 4 female children with diagnosis of refractory
epilepsy, admitted to the pediatric neurology hospitalist service
between October 2013 and June 2014. The inclusion criteria
were: confirmed diagnosis of epilepsy, refractoriness to ASDs,
age ranging from 0 to 14 years, and informed consent signed
by parents. Whereas, exclusion criteria were acute or chronic
metabolic diseases unrelated to epilepsy and the lack of adherence
to the nutritional protocol. The KD was administered by starting
with a 2:1 ratio of lipids and proteins + carbohydrates and,
after few days, shifting to a 3.5/4:1 ratio as detailed previously
(2, 17). KD was monitored and supplemented as previously
described (2, 17). Height, weight and body mass index (BMI)
were measured before the KD onset and until the end of
observation period. Data about demographic features, clinical
characteristics, diagnostic findings, therapeutic interventions,
and clinical outcomes are reported in Table 1. The Ethics
Committee of Modena (4206/C.E.) approved the research
protocol according to local regulations and informed written
consent was obtained from relatives of participants.
Quantitative Analysis of Ghrelin
Reagents and Materials
To block conversion of ghrelin to des-acyl ghrelin (18), we used
the protease inhibitor cocktail P2714 from Sigma Aldrich (Milan,
Italy). The enzyme-linked immunosorbent assay (ELISA) kit for
human plasma acyl ghrelin (EZGRA-88K) was obtained from
Merck Millipore (Milan, Italy).
Sample Processing
Fasting blood samples (8:00–9:00 a.m.) were obtained (3mL)
and coded to assure a blind processing for immunoassays. Blood
collected in tubes with dipotassium ethylenediaminetetraacetate
dihydrate and 10% (v/v) P2714 was gently shaken and quickly
placed on ice, then 15min centrifuged (1,800 g at 4◦C) to
store plasma into sterile microtubes (200 µL) at −80◦C.
4-(2-aminoethyl) benzenesulphonyl fluoride hydrochloride,
contained in P2714, was previously shown to block ghrelin
des-acylation effectively even when samples were kept frozen for
months (18).
Immunoassays
Immunoassays were performed according to instructions.
Samples were processed all together. Standards, controls, and
coded samples were added to plates coated with the primary
antibody and incubated at room temperature (RT) for 2 h. Then,
plates were washed (300 µL to each well) five times and the
enzyme added (100 µL) and incubated at RT for 2 h. After
rewashing, substrate solution (200 µL) was dispensed to wells.
Then, plates were gently shaken in the dark at RT for at least
30min. Each well was mixed, and absorbance measured at
414 nm using a microplate reader (DTX 880 multimode detector,
Beckman Coulter, USA). A cubic polynomial fitting was used to
determine concentrations from the calibration curves. The intra-
assay coefficient of variation (%) for ghrelin was 3.8, instead the
inter-assay coefficient of variation was 7.5.
Statistics
Data from immunoassays, height and body mass index values
were all analyzed using one-way analysis of variance with
repeated measures followed by Duncan’s test for comparisons.
All statistical analyses were performed using Sigmaplot 13 (Systat
Software, San Jose, CA). Data are presented as mean ± standard
error of the mean and regarded significantly different at P < 0.05.
RESULTS
We examined a small cohort of patients affected by refractory
epilepsy, composed by 2 males and 4 female children. The
mean age was 5.9 ± 1.1 year, ranging from 3.0 to 10.4
years. Demographic and clinical features of these children are
illustrated in Table 1. In order to monitor the response to
KD, patients’ ketosis was daily assessed and ranged from 2
to 5 mmol/L. The reduction in seizure frequency obtained by
administering the KD was satisfactory in all patients (>50%):
2 patients displayed more than 75% reduction, while the other
4 patients rarely presented seizures as recurrence was −90% of
previous frequency. However, KD adjustments were required
to obtain an effective control of seizures in the majority of
children (Table 2). Nobody stopped to take ASDs and all were
on polytherapy.
Concerning growth, we calculated z scores immediately before
the KD onset (−0.670 ± 0.739, n = 5), 90 days later (0.002 ±
0.295, n = 5), and at the end of our study (365 days; −1.198 ±
0.763, n = 6). Although we did not find significant differences,
changes in the z score values were differently influenced by the
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TABLE 1 | Demographic and clinical features of patients treated with the ketogenic diet.











(mmol/L, mean ± SEM)
Side
effects
F (1) 7.2 2.6 Spasm Metabolic CBZ, LEV,
NZP
Classic 2:1 >75 3.9 ± 0.2 Hypercholesterolemia;
Hyperoxaluria
F (2) 10.4 10.2 Spasm,
Drop Attack,
TC
Unknown CBZ, LEV Classic 4:1 >75 3.7 ± 0.1 Constipation;
Vomiting
F (3) 4.2 4.2 Drop Attack,
Myocl,
Ab
Structural LEV, TPM Classic 2:1 >90 4.1 ± 0.1 Hypercholesterolemia
M (1) 5.2 2.3 TC,
Drop Attack
Unknown LEV, TPM Classic 3:1 >90 3.3 ± 0.2 –




MCT 3.5:1 >90 3.6 ± 0.1 Nausea;
Vomiting




Classic 4:1 >90 4.5 ± 0.2 –
Ketosis levels were calculated by averaging all values obtained during each week. Ab, absence; ASDs, antiseizure drugs; CBZ, carbamazepine; KD, ketogenic diet; LEV, levetiracetam;
Myocl, myoclonus; NZP, nitrazepam; RFN, rufinamide; SEM, standard error of the mean; TC, tonic-clonic; TPM, topiramate; VPA, valproate; VGB, vigabatrin.
TABLE 2 | Ketogenic diet (KD) was adapted to satisfy every specific requirement, as well as to obtain an adequate seizure control.
Sex Energy intake (kcal/day) Lipids (%) Proteins (%) Carbohydrates (%) Number ofmeals/day Required adjustments
F (1) 800 82 11 7 4 3
F (2) 1,600 89 8 3 4 2
F (3) 1,300 82 8 10 3 2
M (1) 1,250 87 5 8 4 4
F (4) 1,400 89 6 5 3 0
M (2) 1,350 90 8 2 3 3
When seizure control was not satisfactory, the KD was adjusted. Only final KDs are reported in table.
KD timing (Figure 1). Specifically, height z scores were reduced
in 3 out of 5 patients at the end of the study, and in 2 of them
were even lower than those measured at beginning. Surprisingly,
this change occurred after an initial increase of z scores observed
at 90 days in 3 out of 5 children (Figure 1A). From 90 to 365
days, height z scores declined in 4 out of 5 children and only in
one child this trend was the opposite. Concerning BMI z scores,
a reduction was observed in 3 patients at the end of our study,
whereas the other 2 presented a steady increase, at all considered
time intervals (Figure 1B). Average values were: 0.0560 ± 0.913
prior to KD;−0.712± 0.624 at 90 days; 0.155± 0.597 at 365 days.
All the observed changes did not seem to be related to differences
in KDs, as illustrated in Table 2.
Figure 2 illustrates ghrelin levels measured before and after
the KD onset. Consistently, we observed stably reduced ghrelin
plasma levels at 30 (−53%), 90 (−56%), and 365 (−47%) days
after the KD onset. All reductions were statistically significant
when compared with basal levels (P < 0.05 for all the above-
mentioned time intervals, Duncan’s test). It is worth mentioning
that the reduction in ghrelin plasma levels was already detectable
after 15 days (−40%), but it did not reach statistical significance
because two samples were missing for technical reasons.
DISCUSSION
Growth impairment is an adverse event in children with
refractory epilepsy receiving the KD. Although a study initially
reported that growth was normal even after 6 months of KD (4),
all subsequent studies demonstrated that weight and height were
both compromised in the long-term (5–9). Interestingly, lack of
changes at early time intervals was also confirmed by others who
observed that growth impairment occurs only after 6 months of
KD (7). In line with this report, we observed a non-significant
change in growth after 3 months of KD (2), which is further
confirmed by the present results. However, at the end of the study
height z scores were more in line with the consistent findings
reported by others (5–9).
The impact of KD on growth was initially related to the
altered composition of the meal, especially for the reduction in
micronutrients such as oligominerals and vitamins. However,
authors excluded such an interpretation by comparing the effects
on growth of the different KDs currently available to induce
the ketosis (7). Also, the imbalance in protein-to-energy ratio
has been suggested as responsible for the growth impairment
(19). Therefore, we made any effort to carefully maintain a
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FIGURE 1 | Height (A) and body mass index (BMI) (B) z scores were
measured at the beginning of KD (baseline), after 3 months (90 days) and at the
end of the observation period (365 days). Note that z scores were decreased
in 3 patients at the end of the study, with respect to baseline scores. Height
mean values and the respective standard deviation were: −0.670 ± 0.739 (n
= 5) at baseline, 0.002 ± 0.295 (n = 5) 90 days later, and −1.198 ± 0.763 (n
= 6) at the end of study. BMI mean values and the respective standard
deviation were: 0.0560 ± 0.913 (n = 5) at baseline, −0.712 ± 0.624 (n = 5)
90 days later, and 0.155 ± 0.597 (n = 6) at the end of study. Note that one
patient’s data are not illustrated in the figure because height and BMI values
were available only for the last time interval considered in our study.
more than adequate caloric and protein intake, as well as in
giving supplement vitamins and oligoelements to children, as
previously described (2). For this reason, we are prone to believe
that the malfunctioning of GH axis in children receiving the
KD could explain the growth impairment. In line with this
interpretation, we found that ghrelin is rapidly reduced and kept
to approximately half basal values by the KD. After the KD onset,
IGF-I is also immediately reduced and stabilized on low levels
up to 1 year (8). As ghrelin is able to stimulate GH release,
we suggest that the reduction in ghrelin levels may explain the
reported reduction in IGF-I levels. To this regard, caution is
needed because lack of any consequence for growth has been
paradoxically found in animals in which ghrelin or its receptor
was deleted (20). However, a missense mutation of GHS receptor
FIGURE 2 | Changes in ghrelin plasma levels in children (n = 6) affected by
refractory epilepsy and maintained on the ketogenic diet up to 1 year. *P <
0.05, one-way analysis of variance with repeated measures followed by
Duncan’s test.
segregating with short stature was reported for two unrelated
families and, at least in one family, IGF-1 levels were markedly
reduced (21). Consistently, growth velocity was increased in
children of these families who received administration of GH.
The reason for this phenomenon could be the reduced gastric
ghrelin expression and secretion observed in high-fat fed mice
(22), suggesting that the same phenomenon may occur in
patients receiving the KD. However, it has to be mentioned that
also low carbohydrate high fat diets used for treatment of obesity
have been found to modify ghrelin levels (23, 24). In these diets,
the lipids and proteins+ carbohydrates ratio is much lower than
that recommended for refractory seizures. Moreover, restriction
in energy intake is always present and adults are the main
population involved in the studies, whereas KDs for epilepsy are
usually proposed to children for whom no energy restriction is
provided. So, the reported changes in ghrelin levels in response to
reduction in carbohydrate intakemay depend on factors different
from those affecting ghrelin in children with epilepsy and on the
KD. Additionally, results on changes in ghrelin level associated
with reduction in carbohydrates intake were also controversial,
since in one study ghrelin was reduced by 18% (23), whereas in
another one an increase of 7% was observed (24). The magnitude
of these changes was anyway not comparable to that found in our
children, suggesting that the reduction in carbohydrates in KD
does not completely explain our findings.
The reduction in ghrelin availability could result in other,
less evident consequences apart from the growth impairment.
Ghrelin has been identified as an anticonvulsant peptide (13).
We recently found that ghrelin plasma levels are higher in
children responding to ASDs, but not in those with refractory
epilepsy (15). For this reason, the observed reduction in
ghrelin availability due to KD may be unfavorable for the
optimal control of seizures. Contrary to this hypothesis, in
our children we observed a more than satisfactory reduction
in seizure frequency. However, we suspect that the reduction
in ghrelin levels may be involved in other phenomena. For
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instance, we described a paradoxical response in patients
who developed increased seizure frequency and severity
when starting the KD (17). To tentatively investigate this
paradoxical response, in a seizure model we observed a
prolongation of electrographic discharge induced by 6-Hz
corneal stimulation in mice receiving the KD for a week.
However, it remains to be established if ghrelin can play a role
in these phenomena.
Ghrelin has also been demonstrated to possess protective
properties in models of neuronal and vascular lesion [reviewed in
Lucchi et al. (14)]. Indeed, ghrelin was found to attenuate kainic
acid-induced neuronal cell loss in the mouse hippocampus (25).
The ghrelin analog JMV-1843 rescued neurons and astrocytes
in the pilocarpine model of status epilepticus (26). Beneficial
effects were also reported for ghrelin in models of cerebral
ischemia, although they have still to be clearly defined (27, 28).
Interestingly, low ghrelin levels have been related to enhanced
risk of liver damage in children undergoing surgery (29).
This suggests that the reduction in ghrelin levels we observed
in children with refractory epilepsy and receiving the KD
may potentially expose to various consequences and should
be addressed in order to prevent any of the possibly related
adverse effects.
In conclusion, our study identified a long-lasting reduction in
ghrelin levels in children with refractory epilepsy addressed by
KD and receiving an adequate energy intake. The reduction in
ghrelin availability could be related to the slower growth observed
in children on KDs. However, a study based on a larger cohort
is required to definitely demonstrate the association between the
changes in ghrelin production and growth impairment due to
the KD.
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